Kerry Assil, MD
Ophthalmology · Beverly Hills, CANPI 1962436311
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $42,863 of the $50,498 with a category attached, or 84.9%. Johnson & Johnson Surgical Vision, Inc. accounts for 92.6% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2019 at $18,826 and has fallen 98.0% since, to $370 in 2025. Among ophthalmology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 137 payments — averaging $368.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson Surgical Vision, Inc.$47K
- Lensar, Inc.$908
- AbbVie$469
- Alcon$285
- Sun Pharmaceutical Industries Inc.$265
- Bausch & Lomb, A Division Of Bausch Health US, LLC$231
- plus $2K from 20 others
Across 32 payments — averaging $6609.30 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ocular Therapeutix, Inc.$133K
- AbbVie$53K
- Johnson & Johnson Surgical Vision, Inc.$14K
- Sight Sciences, Inc.$9K
- Ophtec USA, Inc.$3K
Across 7 payments — averaging $14,285 each. An ownership or investment interest held by the physician or an immediate family member.
- Ossio LTD$100K
- Ossio Inc$0
What the payments were for
- Consulting fees$42,86385%
- Speaking & faculty fees$260%
- Travel & lodging$2,6295%
- Food & beverage$4,85910%
- Education$430%
- Gifts$450%
- Entertainment$340%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson Surgical Vision, Inc. | 46 | $46,771 |
| Lensar, Inc. | 3 | $908 |
| AbbVie(2 entities) | 20 | $469 |
| Alcon | 8 | $285 |
| Sun Pharmaceutical Industries Inc. | 10 | $265 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 10 | $231 |
| Carl Zeiss Meditec, Inc. | 1 | $203 |
| Ophtec USA, Inc. | 1 | $197 |
| Carl Zeiss Meditec USA, Inc. | 3 | $161 |
| Bausch & Lomb Americas Inc. | 4 | $156 |
| Ocular Therapeutix, Inc. | 5 | $139 |
| Glaukos Corporation | 1 | $123 |
| Tarsus Pharmaceuticals, Inc. | 2 | $79 |
| Sight Sciences, Inc. | 1 | $72 |
| Thea Pharma Inc. | 3 | $64 |
| Mallinckrodt Hospital Products Inc. | 2 | $56 |
| Amgen(2 entities) | 2 | $44 |
| Travere Therapeutics, Inc. | 6 | $43 |
| Rxsight Inc | 2 | $42 |
| Staar Surgical Company | 1 | $39 |
| Revance Therapeutics, Inc. | 1 | $37 |
| Optos, Inc. | 1 | $34 |
| Akorn, Inc. | 1 | $25 |
| Biotissue Holdings Inc. | 1 | $22 |
| Oyster Point Pharma, Inc. | 1 | $20 |
| Galderma Laboratories, L.p. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Catalys Laser System$11,159
- COMPACT INTUITIV Phacofragmentation System$10,125
- Tecnis Multifocal Family of 1-piece IOLS$9,450
- STAR S4 IR$7,088
- Compact Intuitiv$3,281
- IFS ADVANCED FEMTOSEC LASER$3,281
- INTRALASE FS FEMTOSEC LASER$3,281
- Tecnis Symfony IOL$1,034
- Whitestar Phacoemulsficiation System$1,034
- LENSAR LASER SYSTEM$908
- CATALYS SYSTEM$675
- Tecnis IOL$506
- Tecnis 1-piece IOL$338
- iFS Advanced Femtosecond Laser$338
- AMO PHACO NEEDLE$323
- KXL System$123
- Photrexa$123
How this compares
$50,498 in reported general payments places this provider in the 95th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ProlensaBromfenac Sodium | 101 | $33,903 |
| Prednisolone Acetate | 420 | $19,869 |
| Bromfenac Sodium | 64 | $12,462 |
| XiidraLifitegrast | 16 | $11,055 |
| RestasisCyclosporine | 15 | $9,513 |
| Gatifloxacin | 247 | $9,216 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 39 | $8,182 |
| Brimonidine Tartrate | 21 | $4,432 |
| AlrexLoteprednol Etabonate | 11 | $4,201 |
| XalatanLatanoprost | 11 | $2,917 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 29 | $1,259 |
| Ketorolac Tromethamine | 55 | $1,079 |
| Doxycycline Hyclate | 17 | $1,047 |
| MoxifloxacinMoxifloxacin Hcl | 56 | $1,012 |
| Timolol Maleate | 34 | $856 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Alrex | $231 | $38,104112 claims |
| Bausch & Lomb Americas Inc.Xiidra | $156 | $11,05516 claims |
| AbbVieRestasis | $469 | $9,51315 claims |
| AlconSimbrinza | $285 | $8,18239 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Beverly Hills
- Raymond DouglasBeverly Hills$1.3M
- Stuart StollBeverly Hills$673K
- Daniel SchwartzSan Francisco$8M
- Michael BerlinWest Hollywood$5.7M
- Gilbert KlimanMenlo Park$1.5M
- Kuldev SinghStanford$1.5M
- John AffeldtLoma Linda$1.1M
- Srinivas SaddaPasadena$1M
- Sheri RowenNewport Beach$1M
- Savak TeymoorianLaguna Hills$955K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.